Stockysis

Article

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $79

Benzinga Newsdesk | Feb 18, 2026 20:24 | Source: www.benzinga.com

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $128 to $79.

Comments